补肾祛瘀活血汤治疗慢性肾小球肾炎患者的效果分析

目的　探讨补肾祛瘀活血汤对慢性肾小球肾炎患者肾功能及血脂的影响。方法　本研究为前瞻性研究。选取2019年7月至2021年7月临清市人民医院收治的96例慢性肾小球肾炎患者，按随机数字表法将其分为对照组和试验组，每组48例。对照组男25例，女23例，年龄（49.67±8.52）岁；试验组男26例，女22例，年龄（49.53±8.67）岁。两组均予以常规治疗，同时对照组给予氯沙坦治疗，试验组在对照组的基础上给予补肾祛瘀活血汤治疗，两组均连续治疗6个月。比较两组治疗后临床疗效，治疗前后肾功能、血脂指标水平，治疗期间不良反应情况。统计学方法采用独立样本t检验、配对t检验、χ²检验。结果　治疗后试验组临床总有效率与对照组相比升高［93.75%（45/48）比79.17%（38/48）］，两组比较差异有统计学意义（χ²=4.360，P=0.037）；治疗后试验组的血清肌酐（Scr）、尿素氮（BUN）、24 h尿蛋白定量（24 h UP）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）水平均低于对照组［（89.46±10.34）μmol/L比（125.35±14.18）μmol/L、（3.27±0.52）mmol/L比（6.58±0.75）mmol/L、（0.76±0.12）g/24 h比（1.45±0.27）g/24 h、（1.51±0.35）mmol/L比（2.13±0.37）mmol/L、（4.83±0.57）mmol/L比（6.76±0.75）mmol/L、（1.72±0.24）mmol/L比（3.15±0.45）mmol/L］，差异均有统计学意义（均P<0.001）；与治疗前比较，治疗后两组患者的肾小球滤过率（GFR）、血清高密度脂蛋白胆固醇（HDL-C）水平均升高，且试验组的GFR、HDL-C水平均高于对照组［（91.18±6.16）ml/（min·1.73 m²）比（75.35±9.74）ml/（min·1.73 m²）、（1.48±0.25）mmol/L比（1.16±0.23）mmol/L］，差异均有统计学意义（均P<0.001）。两组治疗期间均无严重不良反应出现。结论　补肾祛瘀活血汤治疗慢性肾小球肾炎，可有效缓解患者的临床症状，改善肾功能，调节血脂水平，且疗效显著。

Effect analysis of Bushen Quyu Huoxue decoction in the treatment ofpatients with chronic glomerulonephritis

Objective　To investigate the effects of Bushen Quyu Huoxue decoction on the renalfunction and blood lipid in patients with chronic glomerulonephritis. Methods　It was a prospective study. A total of 96 casesof chronic glomerulonephritis were selected from The People's Hospital ofLinqing from July 2019 to July 2021, and they were divided into a control group(48 cases) and an experimental group (48 cases) with the random number tablemethod. There were 25 males and 23 females in the control group, aged(49.67±8.52) years; there were 26 males and 22 females in the experimentalgroup, aged (49.53±8.67) years. Both groups were given routine treatment, thecontrol group was given losartan treatment, and the experimental group wasgiven Bushen Quyu Huoxue decoction on the basis of the control group. The twogroups received continuous treatment for 6 months. The clinical effect, renalfunction, blood lipid level, and adverse reactions during the treatment werecompared between the two groups. Independent sample t test was used for inter-group comparison of the measurement data,paired t test was used forintra-group comparison of the measurement data, and χ² test was used for the count data. Results　After treatment, the total clinical effectiverate of the experimental group was higher than that of the control group[93.75% (45/48) vs. 79.17% (38/48)], with a statistically significantdifference (χ²=4.360, P=0.037). After treatment, the levels ofserum creatinine (Scr), urea nitrogen (BUN), 24 h urine protein quantification(24 h UP), triglyceride (TG), total cholesterol (TC), and low-densitylipoprotein cholesterol (LDL-C) in the experimental group were lower than thosein the control group [(89.46±10.34) μmol/L vs. (125.35±14.18) μmol/L,(3.27±0.52) mmol/L vs. (6.58±0.75) mmol/L, (0.76±0.12) g/24 h vs. (1.45±0.27)g/24 h, (1.51±0.35) mmol/L vs. (2.13±0.37) mmol/L, (4.83±0.57) mmol/L vs.(6.76±0.75) mmol/L, (1.72±0.24) mmol/L vs. (3.15±0.45) mmol/L], withstatistically significant differences (all P<0.001).After treatment, the glomerular filtration rates (GFR) and serum high densitylipoprotein cholesterol (HDL-C) levels in the two groups were increasedcompared with those before treatment, and the GFR and HDL-C in the experimentalgroup were higher than those in the control group [(91.18±6.16) ml/(min•1.73 m²)vs. (75.35±9.74) ml/(min•1.73 m²), (1.48±0.25) mmol/L vs.(1.16±0.23) mmol/L], with statistically significant differences (all P<0.001). No serious adversereactions were observed in the two groups during the treatment. Conclusion　Bushen Quyu Huoxuedecoction can effectively relieve the clinical symptoms in patients withchronic glomerulonephritis, improve their renal function, and regulate theblood lipid level, with a significant effect.